Clinical Trial Update: Camrelizumab Combined With Chemotherapy and Apatinib for Extrapulmonary Neuroendocrine Carcinomas [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating camrelizumab with chemotherapy and apatinib in extrapulmonary neuroendocrine carcinomas is ongoing with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extrapulmonary Neuroendocrine Carcinoma

Drugs mentioned

• Apatinib (apatinib)
• Camrelizumab (camrelizumab)
• Chemotherapy (chemotherapy)

Snippet

Sponsor: Huazhong University of Science and Technology | Conditions: Advanced or Metastatic EP-NEC | Phase 2 | Status: UNKNOWN